Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Sues To Delay Ranbaxy Lipitor Generic Another Six Years (India)

This article was originally published in PharmAsia News

Executive Summary

Pfizer has filed two more patent suits against Ranbaxy Laboratories, this time in the United States, to extend protection of the anti-cholesterol Lipitor (atorvastatin calcium) patent until 2016. Ranbaxy's atorvastatin generic currently can be sold in the United States beginning in 2010. Pfizer contends those sales of the drug would infringe on its patent on Caduet, a combination of Lipitor and Norvasc (amlodipine besylate), by itself indicated for hypertension. Previous court wins by Ranbaxy allowed the firm to launch its Lipitor generic in 2010, a year ahead of expiration of Pfizer's patent on the drug.(Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068030

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel